{"id":"tim3","name":"TIM-3","symbol":"HAVCR2","route":"/targets/tim3/","asOf":"2026-09-08","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18437","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135077","uniprot":"https://www.uniprot.org/uniprotkb/Q8TDQ0/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q8TDQ0","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4630879","open-targets":"https://platform.opentargets.org/target/ENSG00000135077","civic":"https://civicdb.org/genes/84868/summary","oncokb":"https://www.oncokb.org/gene/HAVCR2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=HAVCR2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=HAVCR2","depmap":"https://depmap.org/portal/gene/HAVCR2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000135077-HAVCR2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/84868","omim":"https://www.omim.org/entry/606652"}],"products":[{"id":"azd7789","name":"AZD7789","status":"phase-2","modality":"bispecific antibody","route":"/drugs/azd7789/"},{"id":"lb1410","name":"LB1410","status":"phase-2","modality":"bispecific antibody","route":"/drugs/lb1410/"}],"trials":[{"id":"nct04931654","name":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","nct":"NCT04931654","phase":"1/2","status":"active"},{"id":"nct06468358","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","nct":"NCT06468358","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["astrazeneca","hutchmed"],"keyPapers":["paper-zeidan-lancet-haematol","paper-pardoll-immune-checkpoint-blockade-nrc-2012"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}